SLC6A3 and Parkinson disease: Dopaminergic system drugs include aromatic amino acid decarboxylase (AADC) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, monoamine oxidase B (MAO-B) inhibitors, dopamine transporter (DAT) inhibitors, and dopamine receptor (DR) agonists; serotonergic system drugs are 5-hydroxytryptamine (5-HT) 2A and 2C receptor antagonists; cholinergic system drugs are mainly muscarinic acetylcholine receptor (mAChR) antagonists; adenosine receptor (A2A) inhibitors and glutamate receptor (NMDA) antagonists are considered as other drugs for treating PD [8,9,10,11].